Abstract
<h3>Background</h3> The search for treatments of progressive multiple sclerosis (PMS) necessitates meaningful markers of disease progression for clinical trials. <h3>Aim</h3> We investigated the responsiveness of the MS Muscle Strength scale (MSMSS), a recently developed physician-based instrument, to determine its value as outcome measure in PMS. <h3>Methods</h3> 54 pwPMS (SPMS=45/PPMS=9) were examined using the MSMSS and again >12 months. Group-level and individual-level indices of change were calculated using Rasch-derived estimates. Change in EDSS was used as external criterion of disability progression. <h3>Results</h3> Between examinations, the sample lost strength (mean change in Rasch-derived estimate −0.88 logits; SD 1.08) and became more disabled (mean increase in EDSS 0.20 points; SD 0.56). Group-level indices of change were greater for the MSMSS than the EDSS (ES 0.59 vs 0.17; SRM 0.81 vs 0.36). Paired t-tests were significant for both MSMSS (p<0.001) and EDSS (p=0.013). Guyatt9s responsiveness index for the MSMSS was moderate (0.73). Individual-level loss of strength reached statistical significance in 46% of the group. <h3>Conclusions</h3> The MSMSS was more sensitive to changes occurring within this sample than the EDSS. This finding supports use of the MSMSS as marker for disease severity in clinical trials and epidemiological studies in PMS.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Journal of Neurology, Neurosurgery & Psychiatry
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.